Medspa Growth Strategies | Moxie Blog

The FDA has officially ended the semaglutide shortage, meaning compounded versions will no longer be allowed after April 22, 2025 (503A) and May 22, 2025 (503B). Here's what medspa owners need to know.

With medical aesthetics evolving rapidly, staying compliant is more challenging than ever. Enter Moxie Compliance Defender, the latest tool we’ve added to our all-in-one platform for aesthetic entrepreneurs.

After years of working in high-intensity hospital settings, Dr. Joseph Seif, M.D., sought a new way to provide care that allowed for more balance between his professional and family life. With the support of Moxie, he made the move to aesthetics and opened SM (Seif Medical) Drip, in San Juan Capistrano, California.

See how Michelle Cote, PA-C, gained greater independence and a more fulfilling work-life balance by making the leap from employee to medspa entrepreneur with the help of Moxie.

We’re proud to announce the formation of Moxie’s first-ever Clinical Advisory Board. Composed of Dr. Sheila Barbarino and Dr. David Saadat, both industry-leading experts and key opinion leaders (KOLs) in aesthetic medicine, this advisory board was built to provide strategic guidance to the network of 250+ independent medspas we support. 

Moxie has raised a $10M Series B led by Lachy Groom and Signalfire at nearly 3x of our Series A. Read how we're using this funding to make every independent medspa more profitable and the job of running it more sustainable.